- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04175002
Endometrial Heparin-binding Epidermal Growth Factor Expression
Endometrial Heparin-binding Epidermal Growth Factor Expression in Implantation Window of Obese Women With Polycystic Ovarian Syndrome(PCOS)
Study Overview
Detailed Description
This prospective study is going to be performed at UKM Medical Centre for a duration of 1 year. The PCOS and control women will be recruited from the Medically Assisted clinic in Obstetrics & Gynaecology department.
The sample size of this study is calculated using Power and Sample Size Calculator by Dupont & Plummer 1998 for paired t-test response version 3.1.2; using the endpoint of mean of Hb-EGF expression during window of implantation in predicting successful pregnancy following in vitro fertilization (IVF) rate by Mengling et al. 2016 (11) as one of its specific outcome. The auto-generated sample size using this programme is 8 subjects. Considering the dropout rate of the sample is 30%, the total sample size required in this study is 10 subjects each arm, making a total sample size 40.
The participants are divided into four groups according to PCOS diagnosis and Asian adult population body mass index (BMI):
- Anovulatory PCOS women with a BMI greater than 27 (OB-PCOS)
- Anovulatory PCOS women with a BMI lower than 25 (NW-PCOS)
- Healthy fertile women with a BMI greater than 27 (OB-C)
- Healthy fertile women with a BMI lower than 25 (NW-C)
In the PCOS group, generally anovulatory cycle hence the implantation window during mid-secretory endometrium can be exhibit following a daily oral micronized progesterone (Utrogestan 200mg) for 10 days based on previously published methods.
Volunteers in the control group with a normal regular menses will be counseled regarding the procedure and monitored for ovulation. The endometrial biopsy will be acquired during implantation window (mid-secretory endometrium), which occurred 7-9 days after the ultrasound and urinary LH confirmed ovulation.
Endometrial samples are obtained using the Pipelle de Cornier catheter for all participants. The endometrium sample that is taken is divided into two portions; a portion for histopathological examination (HPE) for endometrial dating and a portion frozen in liquid nitrogen at -80 degrees Celsius for real-time PCR analysis.
For endometrial dating, all samples were analyzed by classical histological analysis according to the criteria of Noyes.
A total amount of RNA was isolated from the endometrial tissue using RNA easy kit by following manufacturer's instruction. Pellet will be suspended in 30ul of RNAase-DNAse free water. Finally, nanodrop will be used to determine the concentration and quality of RNA. By following manufacture's instruction, total RNA will be reversed transcribed to cDNA. The target for cDNA is primers for heparin binding epidermal growth factor. QRT-PCR will be performed using Sybergreen Master Mix and detected using QRT-PCR detector machine in accordance with manufacturer's protocols. The reaction was running in real-time PCR machine with 40 cycles and cycling temperature as follows: 95 ºC for 10 minutes and 15 seconds, 56 ºC for 30 seconds and final dissociation stage: 94 ºC for 15 seconds, 56 ºC for 15 seconds and last 95 ºC for 15 seconds. Relative quantification will be calculated by normalizing against any housekeeping genes available. Positive controls and negative controls will be included in each analysis run.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Muhammad azrai abu, Medical degree
- Phone Number: 60196410944
- Email: azraiabu1983@gmail.com
Study Locations
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
- Recruiting
- Medically Assisted clinic in Obstetrics & Gynaecology department, UKM Medical Centre
-
Contact:
- Muhammad azrai abu, Medical degree
- Phone Number: 60196410944
- Email: azraiabu1983@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
This prospective study is going to be performed at UKM Medical Centre for a duration of 1 years. The PCOS and control women will be recruited from the Medically Assisted clinic in Obstetrics & Gynaecology department.
Patients will be recruited following written consent. Background information such as age, race, parity, menstrual pattern, associated symptoms will be taken. Clinical assessment which includes height, weight, body mass index and hirsutism (determined by a modified Ferriman and Gallwey score) will be performed. The serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), cortisol, prolactin (PRL), dehydroepiandrosterone sulfate (DHEAS), and β-human chorionic gonadotropin (β-hCG) are measured for all participants. A transvaginal ultrasound scan of the ovaries will be obtained. Endometrial samples are obtained using the Pipelle de Cornier catheter for all participant
Description
The inclusion criteria for the study group are:
- All patients between the aged of 18 to 40 years.
- Women diagnosed with polycystic ovarian syndrome fulfilling two out of three Rotterdam criteria (ie, oligo- or anovulation, hyperandrogenism, and polycystic ovaries on ultrasound).
- Healthy volunteer with confirmed fertility (having at least one child previously), with a normal level of basic reproductive hormones and regular interval of the menstrual cycle (26 to 32 days). (Control group)
The exclusion criteria are:
- Smoking
- any hormonal treatment or other drugs to treat anovulation for at least 3 months before the study
- Pregnancy or lactation during the preceding 12 months
- Systemic disease such as endocrine or eating disorders besides PCOS
- Diagnosed with a uterine or ovarian disease.
- Any regular medication such as hormones, herbal substance, statins or corticoids for at least 3 months before the study.
- History of intrauterine device placement.
The inclusion criteria for the control group are:
- All patients between the aged of 18 to 40 years.
- Healthy volunteer with confirmed fertility (having at least one child previously), with a normal level of basic reproductive hormones and regular interval of the menstrual cycle (26 to 32 days).
The exclusion criteria are:
- Smoking
- any hormonal treatment or other drugs to treat anovulation for at least 3 months before the study
- Pregnancy or lactation during the preceding 12 months
- Systemic disease such as endocrine or eating disorders besides PCOS
- Diagnosed with a uterine or ovarian disease.
- Any regular medication such as hormones, herbal substance, statins or corticoids for at least 3 months before the study.
- History of intrauterine device placement.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Anovulatory PCOS women with a BMI greater than 27
|
oral uterogeston 200mg daily to achieve window of implantation from previous study
|
Anovulatory PCOS women with a BMI lower than 25
|
oral uterogeston 200mg daily to achieve window of implantation from previous study
|
Healthy fertile women with a BMI greater than 27
|
|
Healthy fertile women with a BMI lower than 25
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometrial Heparin-binding Epidermal Growth Factor Expression
Time Frame: After 10 days of oral uterogeston 20mg daily
|
For obese and normal BMI PCOS window of implantation based on Noyes criteria
|
After 10 days of oral uterogeston 20mg daily
|
Endometrial Heparin-binding Epidermal Growth Factor Expression
Time Frame: After 5 days of positive urinary LH
|
For obese and normal BMI normal fertile women window of implantation based on Noyes criteria
|
After 5 days of positive urinary LH
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hormonal assay
Time Frame: During day 2-6 of menstrual cycle
|
During day 2-6 of menstrual cycle
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Mengling S, Xian X, Yongli L, et al. Expression of heparin-binding epidermal growth factor in the endometrium is positively correlated with IVF-ET pregnancy outcome. Int J Clin Exp Pathol 2016;9(8):8280-8285.
- Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan;97(1):28-38.e25. doi: 10.1016/j.fertnstert.2011.09.024. Epub 2011 Dec 6.
- Joham AE, Boyle JA, Ranasinha S, Zoungas S, Teede HJ. Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women's Health. Hum Reprod. 2014 Apr;29(4):802-8. doi: 10.1093/humrep/deu020. Epub 2014 Feb 18.
- Bellver J, Martinez-Conejero JA, Labarta E, Alama P, Melo MA, Remohi J, Pellicer A, Horcajadas JA. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril. 2011 Jun;95(7):2335-41, 2341.e1-8. doi: 10.1016/j.fertnstert.2011.03.021. Epub 2011 Apr 9.
- Schulte MM, Tsai JH, Moley KH. Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod Sci. 2015 Jan;22(1):6-14. doi: 10.1177/1933719114561552. Epub 2014 Dec 7.
- DeUgarte DA, DeUgarte CM, Sahakian V. Surrogate obesity negatively impacts pregnancy rates in third-party reproduction. Fertil Steril. 2010 Feb;93(3):1008-10. doi: 10.1016/j.fertnstert.2009.07.1005. Epub 2009 Sep 5.
- Piltonen TT. Polycystic ovary syndrome: Endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:66-79. doi: 10.1016/j.bpobgyn.2016.03.008. Epub 2016 Apr 1.
- Large MJ, Wetendorf M, Lanz RB, Hartig SM, Creighton CJ, Mancini MA, Kovanci E, Lee KF, Threadgill DW, Lydon JP, Jeong JW, DeMayo FJ. The epidermal growth factor receptor critically regulates endometrial function during early pregnancy. PLoS Genet. 2014 Jun 19;10(6):e1004451. doi: 10.1371/journal.pgen.1004451. eCollection 2014 Jun.
- Lim HJ, Dey SK. HB-EGF: a unique mediator of embryo-uterine interactions during implantation. Exp Cell Res. 2009 Feb 15;315(4):619-26. doi: 10.1016/j.yexcr.2008.07.025. Epub 2008 Aug 3.
- Jessmon P, Leach RE, Armant DR. Diverse functions of HBEGF during pregnancy. Mol Reprod Dev. 2009 Dec;76(12):1116-27. doi: 10.1002/mrd.21066.
- Wirstlein PK, Mikolajczyk M, Skrzypczak J. Correlation of the expression of heparanase and heparin-binding EGF-like growth factor in the implantation window of nonconceptual cycle endometrium. Folia Histochem Cytobiol. 2013;51(2):127-34. doi: 10.5603/FHC.2013.0020.
- Zang H, Sahlin L, Masironi B, Eriksson E, Linden Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab. 2007 Jun;92(6):2169-75. doi: 10.1210/jc.2006-2171. Epub 2007 Mar 6.
- Hulchiy M, Nybacka A, Sahlin L, Hirschberg AL. Endometrial Expression of Estrogen Receptors and the Androgen Receptor in Women With Polycystic Ovary Syndrome: A Lifestyle Intervention Study. J Clin Endocrinol Metab. 2016 Feb;101(2):561-71. doi: 10.1210/jc.2015-3803. Epub 2015 Dec 9.
- Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod. 2002 Feb;66(2):297-304. doi: 10.1095/biolreprod66.2.297.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UKM PPI.800-1/1/5/JEP-2019-367
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gene Abnormality
-
Hospitales Universitarios Virgen del RocíoCompletedAcute Aortic Syndrome | Gene AbnormalitySpain
-
Severance HospitalSamsung Medical Center; Asan Medical Center; Kyungpook National University Chilgok...RecruitingBreast Neoplasms | Benign Breast Disease | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation | Germline Mutation AbnormalityKorea, Republic of
-
Second Affiliated Hospital of Guangzhou Medical...Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical...RecruitingCancer | Lung Cancer | Gene Product Sequence Variation | Gene AbnormalityChina
-
Hunan Cancer HospitalCompletedMetastatic Breast Cancer | Circulating Tumor DNA | Gene Abnormality
-
Hunan Cancer HospitalCompletedMetastatic Breast Cancer | Circulating Tumor DNA | Gene Abnormality
-
Nanfang Hospital of Southern Medical UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First People's Hospital... and other collaboratorsCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia | Gene Abnormality | Cytogenetic AbnormalityChina
-
Assiut UniversityUnknownAsthma | Gene AbnormalityEgypt
-
Henan Cancer HospitalRecruitingLymphoma | Gene AbnormalityChina
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Peking University Third HospitalRecruitingCruciate Ligament Rupture | Meniscus Injury | Gene AbnormalityChina
Clinical Trials on utrogestan
-
HaEmek Medical Center, IsraelCompletedPreterm LaborIsrael
-
University Hospital Inselspital, BerneTerminatedMenopause | Weight Gain | ProgesteroneSwitzerland
-
Chiu Yee Liona PoonWithdrawnPremature Birth | Twin PregnancyHong Kong
-
HaEmek Medical Center, IsraelTerminated
-
Joint Stock Company "Farmak"Completed
-
QH Medical Technology Ltd.Not yet recruiting
-
Rigshospitalet, DenmarkThe Danish Medical Research Council; AP Moeller Foundation; The Danish Medical...CompletedPreterm DeliveryDenmark, Austria
-
University of AthensIaso Maternity Hospital, Athens, GreeceRecruiting
-
King's College Hospital NHS TrustCompletedProgesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled TrialPreterm Birth | Pregnancy Trimester, SecondChile, Brazil, Greece, United Kingdom
-
Joint Stock Company "Farmak"Completed